Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/09/22
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational ProgressGlobeNewsWire • 05/09/22
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare ConferenceGlobeNewsWire • 05/03/22
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature MedicineGlobeNewsWire • 03/28/22
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/26/22
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor ConferencesGlobeNewsWire • 03/24/22
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/18/22
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational ProgressGlobeNewsWire • 02/28/22
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial EnterpriseBenzinga • 01/18/22
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of DirectorsGlobeNewsWire • 01/18/22
Krystal Biotech: Healing 'Butterfly Children' One Topical, Re-Dosable Gene Therapy At A TimeSeeking Alpha • 12/03/21
Krystal Biotech Announces Pricing of $200 Million Public Offering of Common StockGlobeNewsWire • 12/01/21
Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin IndicationsSeeking Alpha • 11/30/21
Krystal Biotech Announces Proposed $200 Million Public Offering of Common StockGlobeNewsWire • 11/29/21
KRYS Stock Alert: The Study Results That Have Krystal Biotech Rocketing 118% TodayInvestorPlace • 11/29/21